The new Irish drug pricing deal, aimed at achieving savings of €785m over four years, provides for regular price cuts and rebates, price reductions for biologicals when biosimilar versions are marketed, and a new mechanism for dealing with high-cost medicines.
The drug pricing agreement between the Irish Pharmaceutical Healthcare Association and the Irish government, which is expected to bring savings of €785m through across-the-board annual price reductions over the next four years, finally came into effect this month despite fears earlier this year that talks on the deal had reached an impasse and might be abandoned.
Under the new framework agreement, pharmaceutical prices will be reduced each year until 2019. Prices will be set...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.
The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
